|
|
Post by yossarian on Jul 12, 2016 10:48:47 GMT -5
|
|
|
|
Post by peppy on Jul 12, 2016 11:00:36 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 12, 2016 11:01:34 GMT -5
so first milestone by end of year?
|
|
|
|
Post by peppy on Jul 12, 2016 11:12:48 GMT -5
so first milestone by end of year? board members, please take a picture of the grant information or information linked to mankind and dumb it down for me.
mannkind and the gates foundation would be a big deal.
|
|
|
|
Post by yossarian on Jul 12, 2016 11:19:06 GMT -5
Reduction of Maternal Death Through Postpartum Hemorrhage: A Highly Heat-Resistant Form of Oxytocin That Does Not Require Injection
Robin OffordThe Mintaka Foundation for Medical ResearchGeneva, Switzerland
Grand Challenges for Development
Saving Lives at Birth
1 Jan 2016
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 12, 2016 11:23:40 GMT -5
There is no mention of MNKD.
Mintaka Foundation gets grant from Gates Foundation.
|
|
|
|
Post by agedhippie on Jul 12, 2016 11:37:42 GMT -5
Here you go - Mintaka Foundation ProjectMany deaths by bleeding could be prevented by an immediate intravenous injection of the drug oxytocin. However, oxytocin is unstable in warm climates and trained staff are not always available to give injections. With MannKind Corporation (USA), we have formulated oxytocin in a dry, stabilized form which can be loaded into a robust, very inexpensive, disposable inhaler, eliminating at the same time the need for injection. Administration by inhalation at last makes treatment possible outside centres with trained medical staff.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 12, 2016 11:53:31 GMT -5
1 JAN 2016 is the date of award. so old news?
Initial grants of $100,000 are awarded, and successful projects have the opportunity to receive follow-on funding of up to $1 million. Winning grants are chosen approximately 5 months from the submission deadline.
|
|
|
|
Post by kbrion77 on Jul 12, 2016 11:55:14 GMT -5
Really confused by this thread. Is it breaking news that a grant was awarded to Mintaka from B&M Foundation?
|
|
|
|
Post by mydogskip on Jul 12, 2016 12:02:50 GMT -5
Really confused by this thread. Is it breaking news that a grant was awarded to Mintaka from B&M Foundation? Not breaking news. There is no relationship between Mannkind and the Gates Foundation. The Gates Foundation has seeded money to many groups trying to solve this problem and this non profit is one of them. Looking at their website, Mannkind has been gracious to provide Technosphere to produce the inhaled oxy but that's it. For anyone to say that there is some secret relationship between Gates and Mannkind is only making it up in their head. Mannkind's only focus is on Afrezza for their survival. It 's not going to waste its time on a non profit working on inhaled oxytocin that is years away from ever seeing any third world using it. |
|
|
|
Post by peppy on Jul 12, 2016 12:31:22 GMT -5
Really confused by this thread. Is it breaking news that a grant was awarded to Mintaka from B&M Foundation? Not breaking news. There is no relationship between Mannkind and the Gates Foundation. The Gates Foundation has seeded money to many groups trying to solve this problem and this non profit is one of them. Looking at their website, Mannkind has been gracious to provide Technosphere to produce the inhaled oxy but that's it. For anyone to say that there is some secret relationship between Gates and Mannkind is only making it up in their head. Mannkind's only focus is on Afrezza for their survival. It 's not going to waste its time on a non profit working on inhaled oxytocin that is years away from ever seeing any third world using it. ok. I want to talk about the gates foundation for a second. My take is it never hurts to have friends in high places.
Regarding the gates foundation, the news media reports their number one objective malaria. It would seem the problem has been solved. Gene editing can now change an entire species -- forever | Jennifer Kahn
www.youtube.com/watch?v=OI_OhvOumT0
malaria engineered out of mosquito. spread the word
|
|
|
|
Post by nylefty on Jul 12, 2016 12:32:03 GMT -5
Really confused by this thread. Is it breaking news that a grant was awarded to Mintaka from B&M Foundation? No. It's old news and a $100,000 grant won't go very far. |
|
|
|
Post by mnholdem on Jul 12, 2016 12:38:18 GMT -5
I think this topic was thoroughly covered in the Monash University thread and this thread is a repeat of what was discussed less than one week ago. 
mnkd.proboards.com/post/73007
|
|
|
|
Post by cm5 on Jul 12, 2016 12:52:47 GMT -5
|
|
|
|
Post by louaboardalia on Jul 12, 2016 17:43:52 GMT -5
This is actually older news, is real, and I have no idea how it materially affects Mannkind. If you go to the Mintaka Foundation website, you will clearly see Mannkind is mentioned:
www.mintakafoundation.org/our-projects/maternal-health/
The discussion is brief and is as follows:
"The Problem
Of the approximately half a million women who die annually from causes related to pregnancy and childbirth, about 99% live in developing countries. For instance, in Chad, on average one girl in 14 who survives growing up will, later in life, die from such causes. The corresponding figure in the developed world is one in 4900 (numbers from WHO – Nov 2015).
At least a quarter of these maternal deaths are a result of uncontrolled bleeding after giving birth.
Our Solution
Many deaths by bleeding could be prevented by an immediate intravenous injection of the drug oxytocin. However, oxytocin is unstable in warm climates and trained staff are not always available to give injections. With MannKind Corporation (USA), we have formulated oxytocin in a dry, stabilized form which can be loaded into a robust, very inexpensive, disposable inhaler, eliminating at the same time the need for injection. Administration by inhalation at last makes treatment possible outside centres with trained medical staff.
Next Steps
Some 98% of our formulation of oxytocin survives 8 months at 40°C, and the inhaler has proved a highly efficient means of delivery. The next step is to design and then execute a clinical safety trial in a developed county (medicines should not be safety-tested on fragile populations). If our expectation that there will be no safety issues proves justified, the way will then be open to forming a product development partnership to take the product to market.
Anticipated Impact
A substantial decrease in the ~140,000 deaths per year and in the number of women (currently 1,600,000) who survive, but in a seriously weakened state. The return to their families of women in good health, ready to care for their children and assume once again their responsibilities in their community."
|
|
